Sabita Sankar

About Sabita Sankar

I am a seasoned biotech executive with over two decades of experience in medical communications, drug development, and diagnostics, all driven by a singular mission: improving patient outcomes in healthcare. With a proven track record of leveraging generative AI and cutting-edge technology, I deliver transformative solutions that enhance medical communications and empower healthcare decisions at scale.My expertise spans oncology, rare diseases, and diagnostics, underpinned by a PhD in Molecular and Cellular Biology and extensive postdoctoral research at Duke and Yale. I have applied my deep domain knowledge to innovate across various roles, including integrating GenAI into medical communications and championing its adoption in medical affairs for impactful outcomes.In my leadership roles at Real Chemistry, Huma.AI, and Ambry Genetics, I have driven business growth by cultivating strategic partnerships, managing multi-million dollar contracts, and creating AI-powered tools for data-driven healthcare solutions. From securing new drug development opportunities to enhancing diagnostics pipelines, my contributions have consistently fueled success and set new industry benchmarks.Highlights:Medical Communications & GenAI: Driving adoption of generative AI, including LLMs, to transform medical affairs and healthcare communications.Drug Development: Bringing two IND candidates to clinical trials while fostering collaborations that streamline processes and enhance therapeutic pipelines.Diagnostics Innovation: Expanding testing menus and forging industry alliances to deliver end-to-end solutions for rare diseases and oncology.Through thought leadership, patents, and publications, I remain at the forefront of innovation, building bridges between technology and patient-centric healthcare.Let’s connect to explore how we can collaborate and innovate for better health o••••••••@gmail.com

Experience

1. Managing Director

   Real Chemistry

   Jan 2023 — Present · Seattle, WA, US

   Real Chemistry is the leading provider of AI-driven insights and human-centric experiences for the healthcare industry.Real Chemistry drives the commercial success of healthcare companies by creating AI-powered, idea-driven healthcare experiences with the customer at the center. Experts from a wide range of disciplines collaborate without barriers under a single, unified mission: to transform what healthcare is to what it should be.SELECTED CONTRIBUTIONS:* Leveraged network of established Pharma clients to successfully secure new business focused on data analytics capabilities.* Played instrumental role in integrating RC into Medical Affairs community through supporting Medical Affairs Professional Society activities including hosting a post Annual meeting webinar and roundtable discussion with key thought leaders. Additionally developed strategy and content for recent Fierce MASS engagement showcasing GenAI capabilities.* Champion for adoption of GenAI capabilities within Medical Affairs including adoption of LLMs for specific use cases.

Education

• National University of Singapore

  Bachelor of Science - BS, Microbiology, Honors Degree

• National University of Singapore

  Doctor of Philosophy - PhD, Molecular and Cellular Biology

  1987 — 1992

Skills

• Business Development
• Immuno-Oncology
• Oncology
• Cell
• Strategic Alliances
• Multiplex Rna Expression
• Droplet Digital Pcr/Qpcr
• Life Sciences
• Molecular Biology
• Protein Chemistry
• Clinical Diagnostics
• Product Development
• Pharmaceutical Industry
• Biomarker Discovery
• Strategic Planning
• Genomics
• Molecular Diagnostics
• Cell Biology
• Project Management
• Sales Forecasts
• Business Strategy
• Science
• Biochemistry
• Translational Research
• High Throughput Screening
• Clinical Trials
• Companion Diagnostics
• Next-Generation Sequencing
• Biotechnology
• Account Management
• Proteomics
• Marketing Strategy
• Drug Development
• Cancer
• Translational Medicine Diagnostics
• Clinical Development
• Drug Discovery
• Precision Medicine
• Contract Proposals
• Budget Forecasts